Hyperpolarized MRI Technology Resource Center

超极化 MRI 技术资源中心

• 批准号: 10410333
• 负责人: Daniel B Vigneron
• 金额: $ 171.12万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10410333
• 关键词: 2,4-Dinitrophenol; Address; Advisory Committees; Algorithms; Biochemical Pathway; Bioreactors; Chemistry; Clinical; Clinical Research; Clinical Trials; Communication; Communities; Computer software; Data; Data Analyses; Development; Documentation; Educational workshop; Environment; Extramural Activities; Funding; Future; Geography; Goals; Growth and Development function; Human; Industry; Infrastructure; Leadership; Magnetic Resonance Imaging; Methodology; Methods; Monitor; Multimodal Imaging; Newsletter; Pathologic; Patient Care; Physician Executives; Physicians; Pre-Clinical Model; Reporting; Research; Research Personnel; Resolution; Resources; Science; Scientist; Services; Site; Software Tools; Structure; Techniques; Technology; Testing; Time; Training; Training Programs; Translating; Translations; Validation; Visualization; Visualization software; clinical translation; data infrastructure; data management; design; detector; human disease; human subject; imaging modality; imaging probe; imaging study; improved; instrumentation; interest; metabolic imaging; molecular imaging; new technology; novel; open source; pre-clinical; pre-clinical research; radiologist; reconstruction; research study; skills; social media; symposium; synergism; technology development; technology research and development; virtual; web site

PROJECT SUMMARY/ABSTRACT The overall goal of this Hyperpolarized MRI Technology Resource Center (HMTRC) renewal project is to develop and disseminate optimal new hyperpolarized (HP) 13C MR technologies with requisite training/documentation to advance significantly this emerging molecular imaging method driven push-pull by 13 Collaborative Projects (10 extramural). Through numerous preclinical and clinical research studies to date, it has become clear both that HP 13C MR has outstanding research and clinical value, but also that virtually all aspects of this technology (instrumentation, agent chemistry, DNP/dissolution methodology, MR acquisition, and data analysis) require specialized developments to realize their full potential. These new technologies, driven “push-pull” by the CPs, will be developed through three Technology Research & Development (TRD) projects and provided to 12 Service Projects (10 extramural) to benefit their funded research and disseminated widely to the general scientific community. TRD1 focuses on technology development for polarizer and RF detector/exciter instrumentation. TRD2 will develop novel HP MR molecular imaging probes tested in realistic preclinical models and correlative science studies. TRD3 will develop new HP C-13 MR acquisition and free, open-source analysis software for the reconstruction, analysis, and visualization of HP MR data specialized for CP and SP needs. This proposed P41 renewal project was recently reviewed by our External Advisory Committee that is comprised of experts in HP 13C MRI, clinical translation, and CP & SP PI’s. Their report states: “The EAC…is unanimous in their assessment that the HMTRC is high functioning as an NCBIB. The HMTRC has led the nation (and the world) in the development and translation of HP MRI through a unique combination of skills, expertise, instrumentation, environment, clinical engagement, and industry engagement, which simply does not exist elsewhere. The HMTRC will continue to serve as a critical national resource through the next funding cycle as the field of HP MRI expands and matures, particularly with the clinical translation of new HP agents, and more sites engaging in research involving human subjects. The restructured Center benefits from clear and enhanced synergy between all TR&Ds and Collaborative Projects that are more broadly geographically distributed. HMTRC programs for training and dissemination remain outstanding. Progress in the engagement and stimulation of clinical interest is nothing short of remarkable, and crucial for the continuing growth and development of this field.” The current P41 project was designed 5 years ago to focus on preclinical HP 13C MR research, since at that time, human studies were only being conducted at UCSF. However, now that many different sites are conducting clinical research studies with the support of this NCBIB, the new renewal P41 is redesigned to facilitate widespread future clinical trials of HP 13C MRI to address unmet clinical needs.

项目摘要/摘要 这个超极化MRI技术资源中心（HMTRC）续订项目的总体目标是 开发和传播必要的最佳新型超极化（HP）13C MR技术 训练/文档以显着推进这种新兴分子成像方法将推动力推动13 协作项目（10个外部）。迄今为止，通过大量临床前和临床研究， HP 13C MR具有出色的研究和临床价值已经很清楚，而且几乎所有都是 该技术的各个方面（仪器，代理化学，DNP/溶解方法，先生，采集， 和数据分析）需要专门的发展才能实现其全部潜力。 这些新技术将由CPS驱动的“推动力”，将通过三项技术研究开发 ＆Development（TRD）项目，并提供给12个服务项目（10个外壁外），以使其资助 研究并广泛传播给了普通科学界。 TRD1专注于技术 偏振器和RF检测器/激发仪的开发。 TRD2将开发新颖的HP MR 在现实的临床前模型和相关科学研究中测试的分子成像问题。 trd3会 为重建，分析，开发新的HP C-13 MR采集和免费的开源分析软件 以及专门用于CP和SP需求的HP MR数据的可视化。 我们的外部咨询委员会最近审查了该拟议的P41更新项目 HP 13C MRI，临床翻译和CP＆SP PI的专家积累。他们的报告指出：“ EAC…是 在评估HMTRC作为NCBIB高功能的一致评估中。 HMTRC领导了 国家（以及世界）在HP MRI的发展和翻译中，通过独特的技能组合， 专业知识，仪器，环境，临床参与和行业参与，这根本没有 存在于其他地方。 HMTRC将通过下一个资金继续作为重要的国家资源 随着HP MRI领域的扩展和成熟，特别是随着新的HP代理的临床翻译的成熟， 以及更多参与涉及人类学科的研究的站点。恢复的中心受益于清晰的 并增强了所有TR＆D和协作项目之间更广泛地理位置的协同作用 分布式。 HMTRC培训和传播计划仍然出色。参与进展 刺激临床兴趣是显着的，对于持续增长和 当前的P41项目是5年前设计的，目的是专注于临床前HP 13C MR Research，因为当时，人类研究仅在UCSF进行。但是，现在有很多 不同地点正在进行临床研究，并在此NCBIB的支持下，新的续签P41是 重新设计以促进HP 13C MRI的未来临床试验，以满足未满足的临床需求。